Fig. 2
From: A novel lipophilic amiloride derivative efficiently kills chemoresistant breast cancer cells
LLC1 selectively reduces the viability of mouse mammary tumors ex vivo. Representative images of LLC1-treated (10 µM) organoids generated from mammary tumors (A) and normal mammary glands (C) from 4T1-engrafted Balb/cJ mice are shown. Scale bar = 100 µm. (B,D) Organoids were treated with 10 µM LLC1, and viability was assessed using RealTime Glo over 72 h and normalized to vehicle treatment (DMSO). Tumor (B) or mammary fat pad (MFP) (D) organoid viability was monitored every 24 h. Data were compiled from three biological replicates that included six to twelve organoids derived from tumors or mammary glands of independent mice. Data are presented as averages ± SEM and significance assessed by t-test. *P < 0.05.
